ESMO 2023

Les supports des 4 communications de la FFCD à l'ESMO 2023 sont désormais consultables en ligne :

4 résultats

REWENEC: REal World Evidence in NEC generate an external control arm to avoid randomization for second-line clinical trials. A post hoc proof of concept analysis with the randomized phase II BEVANEC study - 2023

Impact  of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients – results from the PETACC 8 study - 2023

5-fluorouracil and oxaliplatin with or without docetaxel in first-line treatment of HER2 negative locally advanced unresectable or metastatic gastric or gastro-esophageal junction adenocarcinoma (GASTFOX-PRODIGE 51): a randomized phase 3 trial  - 2023

First results of the French prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)  - 2023